Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Medi-Solfen® has the potential to have a major role in military and mass casualty trauma situations

Military

The recent wars in Iraq and Afghanistan have helped to shape the modern Defence Medical Services. Over the course of these conflicts there were a number of incremental innovations and improvements in clinical techniques and attitudes that contributed to the overall effect of reducing the mortality from combat injury. Significant resources were allocated to prepare for and deliver a coherent plan for deployed trauma care. The medical advances during the recent conflicts in these parts of the world have also included advances in anaesthesia and analgesia, but to a lesser extent than in other areas. The priority has so far been on improving survival rates. The humanitarian and physiological consequences of analgesia have featured less highly on the priority list.

Presently, with the level of small arms and fragment protection that is issued to Armed Forces, the survival rate following combat trauma is approximately 98%; however, there has been an increase in the number of extremity, groin, and facial wounds, as these are areas that are not as well shielded by individual combat armour1. Many of the concerns and obstacles faced by early anaesthesia providers continue to exist today. The needs for safety, rapid application to surface injuries, mobility and availability of logistical resupply are all concerns for military anaesthesia providers.

The ideal analgesic for military use should have a predictable action, no side effects, a long duration of action, a readily available antidote, be easily administered and be easily stored and transported2.

A Combat Medic will typically carry a backpack styled bag known as a “Unit One Pack”. Aid bags are available from many different manufacturers, in many different styles. Depending on the unit and their standard operating procedures, the Medic may have to follow a strict packing list, or may have the liberty of choosing their kit depending on the mission at hand. In terms of analgesics a typical aid bag will include: Morphine, Naproxen and some OTC products such as Acetaminophen and Ibuprofen3. Depending on the injury pain control may involve a combination of simple measures and different drugs. Morphine auto-injectors are issued to many countries’ armed forces on operations. All UK soldiers receive ample training on the use of the morphine auto-injector. Confidence in using the device is high and generally knowledge is good4. Unwanted side effects associated with Morphine use include respiratory depression, constipation and constriction of the pupils of the eye all of which may affect overall performance in combat situations. The goal in a casualty with mild-to- moderate pain is to provide pain relief that does not affect their sensorium. This allows them to either continue to facilitate their mission set or to help facilitate their own medical care and evacuation, depending on circumstances. In the wilderness setting, this would, in particular, apply to the casualties being able to facilitate their own evacuation5. The respiratory depression that is associated with opiate administration may result in the casualty requiring airway support, greatly complicating any movement.

Wound infection following combat injury is a cause of significant morbidity and occasional mortality6. Combat injury is often filthy, with ingrained dirt containing many troublesome microbes, both bacterial and fungal. These sow the seed for problems which may continue for many years after the injury7. Currently there is no provision for the delivery of any topical antimicrobial agents prior to the arrival of the patient at the Field Hospital.

Now that the survival rate has significantly improved following combat injury, perhaps now is the time to concentrate more effort into the humanitarian and other physiological effects of better anaesthesia, as well as ways of reducing the wound infection rate.

Medi-Solfen® offers the potential for a safe, effective replacement for Morphine that can both be easily and quickly applied and have immediate effect. It is important that delivery of these multi-modal anaesthetics has minimal psychoactive effects so that patients can continue to assist in their own care, evacuation and defence. An additional major benefit offered is that these drugs would act only at the wound site and not systemically. The inclusion of adrenaline into the overall formulation could also have a beneficial effect in controlling surface bleeding. Compared with opiates, which are Controlled Substances and Accountable Items, it would be relatively easy to envisage every soldier carrying an application of Medi-Solfen® in his first aid kit. Cost is also a factor in what medications are carried and utilized. Generic non-prescription medications such as Acetaminophen and Ibuprofen are available at minimal cost, whereas morphine injectors are much more expensive. There is also much less potential for criminal abuse of an item such as Medi-Solfen, unlike opiates. The logistics of the issuing of Medi-Solfen should therefore be much less onerous. The individual provider will need to decide which analgesics he or she should carry based on cost as well as regulatory and standard care pathway considerations.

Mass Casualty

In addition to military conflicts disaster situations, such as earthquakes, floods, conflicts, might happen in areas where access to a regular hospital or treatment centres might be hours away or not available at all. The provision of effective analgesia for mass casualties needs to be simple in its scope and application, supporting the principle of providing the greatest good for the greatest number in the safest way. The care of wounded victims, and the building or rebuilding of medical and first-aid facilities falls to the role of humanitarian assistance and disaster relief agencies such as the United Nations, Medecins Sans Frontieres and the IRC. These agencies are funded by donations and/or government funding and grants. Similar to the military, all of these agencies source and supply basic medical necessities to their Field Officers for the management of wounded victims and for the setting up of basic medical facilities. A product like Medi-Solfen® has the potential to become a critical component of the basic medicines supplied. It is ideally suited to such applications because it is cheap, portable and able to be applied immediately by rapidly trained lay personnel. It would provide a means of promptly treating wounds that otherwise may remain untended for prolonged periods of time particularly in war-torn or third-world countries. Indeed in many cases such wounds may not receive any other anaesthetic. The monitoring of such casualties may need to rely on minimally trained personnel using simple clinical parameters. When casualties present in large numbers with minor injuries resulting in breakdown of the skin Medi-Solfen can provide an effective rapid solution to pain relief during potential long waits for initial triage or allow casualties to return for later treatment if not in imminent danger. The benefits of having a cheap, simple to use product to relieve pain, minimise bleeding and protect against infection in these circumstances are considerable. Medi-Solfen® has the potential to act as the ‘front line’ pain relief for topical wound care product for victims of trauma throughout the world.

References

  1. Jeffery SLA. Advanced wound therapies in the management of severe military lower limb trauma: a new perspective. Eplasty 2009; 21: e28
  2. Battlefield Advanced Training Life Support. Chapter 14 Analgesia. JR Army Med Corps (2003); 149: 297-302
  3. Equipment of a combat medic https://www.google.co.uk/search?q=morphine+in+soldiers+combat+back+packs&rlz
    =1C1GCEA_enGB784GB784&oq=morphine&aqs=chrome.1.69i57j35i39j0l4.5917j0j8 &sourceid=chrome&ie=UTF-8
  4. Nelson SC and Wedgwood JT (2015.) How much do soldiers know about the morphine they carry on operations? A questionnaire study of knowledge and understanding of the morphine auto-injector on Op HERRICK 17. J R Army Corps; 161(1): 27-31
  5. Wedmore IS and Butler FK Jr (2017) Battlefield analgesia in Tactical Combat Casualty Care. Wilderness and Environmental medicine;28: S109-S116
  6. Taylor C, Jeffery SLA. Management of military wounds in the modern era. Wounds UK 2009; 5: 50-58.
  7. Jeffery SL. The Management of Combat Wounds: The British Military Experience. Adv Wound Care 2016 Oct 1; 5(10): 464-473.